Persistent pulmonary hypertension of the neonate (persistent fetal circulation syndrome).
This 15-year-old disease has been clearly described anatomically. Some understanding of possible in utero predisposing conditions has emerged from clinical and animal studies. However, we have very little understanding of the cellular processes that trigger and/or prolong the abnormal medial smooth muscle hypertrophy underlying the condition. Empiric observation has resulted in the development of hyperventilation as a fairly successful treatment modality, although the underlying mechanism of this salubrious effect is unknown. Drugs, a major focus of clinical and laboratory investigations, sometimes are marginally successful (and sometimes are utter failures). Translated into the neonatal intensive care unit, the disease is more frequently accurately diagnosed than in the past, but it remains frustratingly difficult to manage, and thus far is impossible to prevent. The research foundations laid in the past decade provide impetus for accelerated search into the fundamental cellular and biochemical derangements that cause persistent pulmonary hypertension. It is to be hoped that the next decade will yield major advances in both mechanistic understanding and in treatment.
D000109:Acetylcholine / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D002395:Catecholamines / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D006706:Homeostasis; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology; D007231:Infant, Newborn; D009119:Muscle Contraction; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D009543:Nifedipine / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010100:Oxygen / Q000627:therapeutic use; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control / Q000628:therapy; D015230:Prostaglandin D2; D011457:Prostaglandins D / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000033:anatomy & histology; D011667:Pulmonary Veins / Q000033:anatomy & histology; D014043:Tolazoline / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D002395:Catecholamines; D011457:Prostaglandins D; D009599:Nitroprusside; D014043:Tolazoline; D014700:Verapamil; D011464:Epoprostenol; D005996:Nitroglycerin; D009543:Nifedipine; D000109:Acetylcholine; D015230:Prostaglandin D2; D010100:Oxygen; D002118:Calcium